Major Sponsors:

tba.

Conference Topics:

The International Neuro4D Conference is focused on Neuro Degenerative Disease Drug Discovery and limited to a maximum of 100 participants. We are inviting drug discovery companies, service and technology providers, and academic innovators in the field of proteopathic neurodegenerative diseases to attend or present at this most interactive event.

Neuro4D brings a limited number of distinguished industry and academic speakers, poster presenters and delegates in neurodegenerative disease in direct contact, and creates lively discussions about drug discovery efforts for two full days, in a stimulating and enjoyable setting. Academic research leaders outline recent insights into disease mechanisms and new pharmaceutical modes of action. Biotech and international pharmaceutical companies present their developments for new treatment options and outline advantages and disadvantages of disease models for compound selection and optimization. Service and technology providers present their platforms and show examples of how their services contribute to the discovery of new drug candidates. By the end of the conference, all participants have gotten to know each other, with some seeding productive collaborations.

During the seventh international Neuro4D 2025 conference, we will focus on neuroinflammation as a major contributor to disease progression and new insights from recent clinical developments. We will look at the potential and ongoing initiatives using new pharmaceutical modalities. The event will be located in the Atrium Hotel and the inspiring environment of Mainz, Germany, with easy access to Frankfurt international airport, the second biggest in Europe. The conference format will be highly interactive again, with a single track, and chairperson-lead podium discussions at the end of each session

All presentations, incl. Q&A, will be exactly 15 min. A chairperson-led podium discussion of 15 min with all speakers of the past session will follow. Chairs will introduce their session subject with a 30 min overview presentation.

Each registered delegate is encouraged to show a poster during the conference to discuss the details of their research. The deadline for poster abstract (max. 300 words) submission 2026, is March 30! They will be checked and confirmed ASAP. Accepted abstracts of participating delegates will be published in the program. Please submit your abstracts in MS Word, or as Email text to the organizer: info@bioexpert.biz.

Poster boards have portrait orientation with a width of 118.5 cm and a height of 146 cm. Posters must have a maximum size of A0 (84 × 119 cm). Poster presenters are requested to be at their posters during dedicated breaks.

Online Registration Fee for 2026 includes: conference hotel accommodation from Sunday, May 3 to Tuesday, May 5 for all delegates, food and drinks during the entire two days of the event, joint social activities, and the highly praised interactive conference dinner on Monday evening.

Conference Venue:

Atrium Hotel Mainz
Flugplatzstraße 44
55126 Mainz
Germany
Tel.: +49 6131 80 15 0
info@atrium-mainz.de
www.atrium-mainz.de

Organizer:

Dr. Andreas Köpke (bioExpert)
Tel: +49 6136 957 3000
info@bioexpert.biz

Topics Highlights:

In 2025 we saw a number of new approvals for diagnoses and treatment of Alzheimer’s and Parkinson’s disease. This gave new hope to pharma companies and investors, slowly re-entering these indications. Texans have devoted 3 billion US$ for the largest state-funded dementia research initiative (DPRIT). The American Alzheimer Association and Michael J. Fox Foundation created funding for scientists that lost their grants in the recent changes of the federal administration. The prion-like properties of toxic soluble protein aggregates in neurodegenerative diseases are now largely accepted in the scientific community, and many companies use these insights to develop new diagnostics and treatments.

On the second day of the conference we focus on clinical applications. Looking closely into new diagnostic and treatment developments and their value for the care of patients. In the final clinical session, we will listen to clinical study results. As always, we will discuss recent developments, clinical outcomes and the benefit for patients and caregivers in a podium discussion at the end of the meeting.

Sponsors:

tba.

Target Audience:

• Drug discovery experts in neurodegenerative diseases from biotech and pharmaceutical industry
• Academic experts in proteopathic neurodegenerative diseases interested in drug discovery
• Service providers of technologies, analytical tools, and models for neurodegenerative diseases
• Pharma strategists and investors interested in the field and prepared to learn and fund the most innovative approaches
• PhDs looking for new positions in the neurodegeneration

Advisory Committee:

Rakez Kayed, UTMB, Galveston, USA
Neil Cashman, ProMIS, Vancouver, Canada
Oliver Peters, Charité, Berlin, Germany
Roger Sher, Stony Brook University, USA
Knut Biber, Abbvie, Germany

Registration:

Corporate*	Academic*
1690 € (additional: 1090 €)	790 €	Early Bird (before March 1)
1990 € (additional: 1290 €)	1090 €	Regular (until April 24)
*all registrations include accommodation in the conference hotel from Sun May 3 to Tue May 5 2026, all meals and drinks during the conference, and the conference dinner on Monday night. Add. Nights: in single superior room in the conference hotel, incl. breakfast: 150 € On Site Registration: at regular price, incl. meals and drinks, but excl. accommodation All prices: plus 19% German VAT, mandatory for events held in Germany
For special arrangements, please contact the organizer at info@bioexpert.biz. Early Bird until and including March 1st, 2026 » register now